Effect of MK0524A on Cholesterol Levels (0524A-048)

PHASE3CompletedINTERVENTIONAL
Enrollment

646

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions
HypercholesterolemiaHyperlipidemia
Interventions
DRUG

laropiprant/niacin (MK0524A)

"Treatment Period 1: one 20mg/1g tablet laropiprant/niacin once daily for 4 weeks~Treatment Period 2: two 20mg/1g tablets laropiprant/niacin once daily for 8 weeks.~All patients will receive placebo for a 4 week run-in period before randomization"

DRUG

Comparator: placebo

"Treatment Period 1: one 20mg/1g tablet placebo to laropiprant/niacin once daily for 4 weeks~Treatment Period 2: two 20mg/1g tablets of placebo to laropiprant/niacin once daily for 8 weeks.~All patients will receive placebo for a 4 week run-in period before randomization."

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00536510 - Effect of MK0524A on Cholesterol Levels (0524A-048) | Biotech Hunter | Biotech Hunter